GeneTAC platform's first clinical signal in Friedreich ataxia hinges on whether 12-week frataxin data can support a registrational path

Design Therapeutics is a clinical-stage gene therapy company developing a treatment for Friedreich ataxia, a rare neurological disorder, that is not yet approved.

Four-week data from 16 Friedreich ataxia patients showed dose-dependent frataxin restoration and a 6.4-point mFARS improvement at the highest dose, setting up the 12-week readout as the pivotal proof point. The thesis resolves on whether 12-week frataxin protein increases are durable and large enough for FDA to accept a registrational path without a full Phase 3. The primary risk is regulatory: Friedreich ataxia lacks precedent for approval on a protein biomarker endpoint alone, and nomlabofusp (Larimar) is competing for the same patients with a different frataxin-restoration mechanism.